Janus Henderson Group
RYTM icon

Janus Henderson Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Janus Henderson Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79.9M Sell
918,153
-207,972
-18% -$20.2M 0.04% 320
2025
Q4 		$121M Sell
1,126,125
-34,762
-3% -$3.69M 0.05% 254
2025
Q3 		$117M Sell
1,160,887
-251,015
-18% -$23.3M 0.05% 255
2025
Q2 		$89.3M Sell
1,411,902
-243,448
-15% -$14.9M 0.04% 285
2025
Q1 		$90.7M Buy
1,655,350
+435,796
+36% +$24.2M 0.05% 278
2024
Q4 		$68.3M Buy
1,219,554
+621,432
+104% +$34.3M 0.03% 326
2024
Q3 		$31.3M Buy
598,122
+4,480
+0.8% +$215K 0.02% 487
2024
Q2 		$24.4M Sell
593,642
-27,785
-4% -$1.11M 0.01% 532
2024
Q1 		$26.9M Sell
621,427
-465
-0.1% -$20.4K 0.01% 513
2023
Q4 		$28.6M Sell
621,892
-443,853
-42% -$14M 0.02% 477
2023
Q3 		$24.4M Sell
1,065,745
-12,462
-1% -$279K 0.02% 496
2023
Q2 		$17.8M Sell
1,078,207
-19,366
-2% -$350K 0.01% 576
2023
Q1 		$19.6M Sell
1,097,573
-142,580
-11% -$3.58M 0.01% 585
2022
Q4 		$36.1M Sell
1,240,153
-1,882,013
-60% -$48.4M 0.03% 444
2022
Q3 		$76.5M Buy
3,122,166
+1,042,089
+50% +$19.4M 0.03% 418
2022
Q2 		$8.63M Sell
2,080,077
-870,925
-30% -$4.77M 0.01% 722
2022
Q1 		$34M Sell
2,951,002
-182,933
-6% -$1.61M 0.02% 611
2021
Q4 		$31.3M Sell
3,133,935
-48,447
-2% -$544K 0.01% 679
2021
Q3 		$41.6M Sell
3,182,382
-743,668
-19% -$11.4M 0.02% 603
2021
Q2 		$76.9M Sell
3,926,050
-161,973
-4% -$3.36M 0.03% 447
2021
Q1 		$87M Sell
4,088,023
-403,742
-9% -$11.7M 0.04% 406
2020
Q4 		$134M Buy
4,491,765
+105,395
+2% +$2.68M 0.06% 302
2020
Q3 		$95.1M Sell
4,386,370
-24,118
-0.5% -$553K 0.05% 343
2020
Q2 		$98.4M Buy
4,410,488
+91,455
+2% +$1.78M 0.06% 318
2020
Q1 		$65.7M Buy
4,319,033
+13,785
+0.3% +$247K 0.05% 381
2019
Q4 		$98.8M Buy
4,305,248
+898,500
+26% +$20M 0.05% 381
2019
Q3 		$73.6M Buy
3,406,748
+114,423
+3% +$2.45M 0.04% 460
2019
Q2 		$72.4M Buy
3,292,325
+10,556
+0.3% +$267K 0.04% 477
2019
Q1 		$90M Buy
3,281,769
+18,594
+0.6% +$534K 0.05% 409
2018
Q4 		$87.7M Buy
3,263,175
+212,337
+7% +$5.87M 0.06% 380
2018
Q3 		$89M Buy
3,050,838
+759,053
+33% +$24M 0.05% 428
2018
Q2 		$71.6M Buy
2,291,785
+1,197,165
+109% +$32.7M 0.04% 458
2018
Q1 		$21.8M Buy
1,094,620
+339,460
+45% +$9.01M 0.01% 779
2017
Q4 		$21.9M Buy
+755,160
New +$20M 0.01% 743

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group's RYTM Position: Q1 2026 in Review

Janus Henderson Group reduced its Rhythm Pharmaceuticals (RYTM) stake by 18% in Q1 2026, selling an estimated $20.2M and leaving 918,153 shares worth $79.9M. The position accounts for 0.04% of the portfolio, ranked #320.

Janus Henderson Group first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $134M in Q4 2020. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Janus Henderson Group held 918,153 shares of Rhythm Pharmaceuticals worth $79.9M as of Q1 2026.
  • Janus Henderson Group sold 207,972 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $20.2M.
  • Rhythm Pharmaceuticals made up 0.04% of Janus Henderson Group's portfolio in Q1 2026, its #320 holding.
  • Janus Henderson Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Janus Henderson Group's Rhythm Pharmaceuticals position peaked at $134M in Q4 2020.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.